Chat GPT8 Dec 2025 10:13
Asked Chat GPT
🧰 Could this apply to Tissue Regenix now — plausible triggers
Based on the recent developments at Tissue Regenix, a legal claim might be considered if you (or others) could demonstrate one or more of the following:
• That the share issue / convertible loan note (CLN) raise + immediate conversion was structured in a way to overwhelmingly benefit the majority shareholder (Harwood Private Equity VI L.P.) at the expense of minority holders — especially if there was little to no attempt to offer minority shareholders any pre-emption or meaningful right to participate.
• That the decision to delist and re-register as private was framed as “in the best interests of company,” but was in actual fact primarily designed to strip liquidity from minority shareholders, limit transparency and consolidate control.
• That the financial mis-statements, restatements of revenue, “operational mis-steps,” supplier issues and cash-flow problems were — if proven negligent or reckless — grounds for a derivative claim for breach of directors’ duties (e.g. mis-management, poor oversight, failure of due diligence). 
• That minority shareholders — including you — were not given sufficient notice, explanation or ability to meaningfully object or protect their interests before major structural changes (CLN, delisting) were approved.
If any of these elements are present (and provable) — there is a potential legal case under UK company law.
⸻
🎯 What realistically you could do right now
1. Document everything: collect all public announcements (RNS, circulars, board statements), any emails or shareholder communications, share register history, and evidence of dilution / conversion details.
2. Seek professional legal advice: a law firm experienced with minority-shareholder claims or corporate disputes should review your case. The threshold is high.
3. See if other minority shareholders join you: a unified petition with several minority shareholders strengthens the case (and spreads legal cost).
4. Act quickly: once the company is re-registered as private, with new articles and no AIM listing — practical ability to get documentation, shareholder information, and to exercise rights becomes more difficult. Time matters.
5. Weigh costs vs. likely outcome: litigation is expensive, uncertain and slow; even a “successful” claim may only result in a court-ordered buyout at a deeply discounted value — or may fail entirely.
⸻
✅ My View: A Legal Case Is Possible — but Risky and Uncertain
Yes, I think there is a realistic basis for a legal claim — particularly if you (or a group of minority shareholders) can show the CLN issue + conversion + delisting was executed primarily to benefit the controlling shareholder and significantly disadvantage minority holders.
However: UK courts tend to be reluctant to interfere with corporate governance — poor business outcomes alone rarely
Sign In
Follow the stocks
